Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Jan 10;29(3):535-44.
doi: 10.1016/j.vaccine.2010.10.046. Epub 2010 Oct 31.

Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age

F M Russell  1 , J R Carapetis, R L Burton, J Lin, P V Licciardi, A Balloch, L Tikoduadua, L Waqatakirewa, Y B Cheung, M L K Tang, M H Nahm, E K Mulholland
Affiliations
Randomized Controlled Trial

Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age

F M Russell et al. Vaccine. .

Abstract

Opsonophagocytic activity (OPA) was measured following reduced infant doses of 7-valent pneumococcal conjugate vaccine (PCV-7) with or without 23-valent pneumococcal polysaccharide vaccine (PPV-23) at 12 months, and subsequent re-exposure to a small dose of pneumococcal polysaccharide antigens (mPPS) at 17 months. Fijian infants were randomized to receive 0, 1, 2, or 3 PCV-7 doses. Half received PPV-23 at 12 months and all received mPPS at 17 months. OPA was performed on up to 14 serotypes. Three and 2 PCV-7 doses resulted in similar OPA for most PCV-7 serotypes up to 9 months and for half of the serotypes at 12 months. A single dose improved OPA compared with the unvaccinated group. PPV-23 significantly improved OPA for all serotypes tested but in general, was associated with diminished responses following re-challenge.

Trial registration: ClinicalTrials.gov NCT00170612.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Pre- and one month post-mPPS OPA titer for serotypes 4 and 6B, in those that did (+) and did not (o) receive PPV-23 at 12 months of age. Data from infants receiving 0, 1, 2, or 3 PCV-7 doses have been combined in these graphs
Footnote: A 45-degree line, which indicates no change before and after the re-challenge (mPPS), is superimposed. The pre- and post-mPPS OPA titer of those who received PPV-23 at 12 months mostly fell along the 45-degree line, indicating no response to mPPS, except for serotypes 1 and 5. In contrast, most children who did not receive PPV-23 had an increase in OPA titer, as indicated by the data points falling above the 45-degree line
Figure 1
Figure 1. Pre- and one month post-mPPS OPA titer for serotypes 4 and 6B, in those that did (+) and did not (o) receive PPV-23 at 12 months of age. Data from infants receiving 0, 1, 2, or 3 PCV-7 doses have been combined in these graphs
Footnote: A 45-degree line, which indicates no change before and after the re-challenge (mPPS), is superimposed. The pre- and post-mPPS OPA titer of those who received PPV-23 at 12 months mostly fell along the 45-degree line, indicating no response to mPPS, except for serotypes 1 and 5. In contrast, most children who did not receive PPV-23 had an increase in OPA titer, as indicated by the data points falling above the 45-degree line
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Conclusions from the WHO multicenter study of serious infections in young infants. The WHO Young Infants Study Group. Pediatr Infect Dis J. 1999 Oct;18(10 Suppl):S32–4. - PubMed
    1. O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009 Sep 12;374(9693):893–902. - PubMed
    1. Bruyn GA, Zegers BJ, van Furth R. Mechanisms of host defense against infection with Streptococcus pneumoniae. Clin Infect Dis. 1992 Jan;14(1):251–62. - PubMed
    1. Austrian R. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Rev Infect Dis. 1981 Mar-Apr;3(Suppl):S1–17. - PubMed
    1. Tuomanen EI, Austrian R, Masure HR. Pathogenesis of pneumococcal infection. N Engl J Med. 1995 May 11;332(19):1280–4. - PubMed

Publication types

Substances

Associated data